Muconasal Plus (Tramazoline Hydrochloride Monohydrate)

Tramazoline hydrochloride is an alpha‑adrenergic receptor agonist. By stimulating these receptors on the blood vessels of the nasal mucosa, it causes vasoconstriction, which reduces swelling and fluid buildup, thereby decreasing nasal blockage.

The appropriate dose of Muconasal Plus is determined by a healthcare professional based on the individual’s age, condition severity, and response to treatment. Patients should follow the prescriber’s instructions and the product label.

Safety data for Tramazoline hydrochloride in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should consult their physician before using Muconasal Plus to weigh potential benefits against risks.

To request Muconasal Plus, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Muconasal Plus contains Tramazoline hydrochloride, an alpha‑adrenergic agonist similar to other topical decongestants like oxymetazoline. Its efficacy in reducing nasal swelling is comparable, but the safety profile, duration of action, and risk of rebound congestion may differ, so clinicians choose based on patient needs and tolerance.

Muconasal Plus should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and extreme temperatures to maintain its stability and effectiveness.

Muconasal Plus is applied intranasally. The user gently inserts the spray tip into each nostril and administers the prescribed number of sprays, usually while keeping the head upright. The medication should be used as directed by a healthcare professional.

Serious risks, though rare, include severe hypertension, cardiac arrhythmias, allergic reactions such as rash or angioedema, and persistent nasal ulceration. Patients should seek immediate medical attention if they experience any of these symptoms.

Muconasal Plus should be avoided by individuals with uncontrolled hypertension, severe cardiovascular disease, known hypersensitivity to Tramazoline hydrochloride, or those who have been advised by a physician to refrain from using topical nasal vasoconstrictors.